Form D · Biotechnology
Alpha Cognition Inc.
Vancouver, A1 · CIK 0001655923
Offering snapshot reported Nov 18, 2024 · SEC filing
- Reported sold
- $0 Offering amount: $347K
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 21, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 18, 2024 | Initial | $0 | No comparison | 1 | SEC filing |
| Oct 9, 2024 | Initial | $4,545,000 | No comparison | 22 | SEC filing |
| Jan 31, 2024 | Initial | $2,839,628 | No comparison | 60 | SEC filing |
| Jan 5, 2024 | Initial | $1,762,097 | No comparison | 30 | SEC filing |
| Nov 20, 2023 | Initial | $1,009,999 | No comparison | 13 | SEC filing |
| Oct 19, 2023 | Initial | $343,999 | No comparison | 9 | SEC filing |
| Sep 12, 2023 | Initial | $1,260,837 | No comparison | 28 | SEC filing |
| Mar 28, 2023 | Initial | $1,286,748 | No comparison | 14 | SEC filing |
| Feb 28, 2023 | Initial | $1,847,827 | No comparison | 8 | SEC filing |
| Oct 18, 2021 | Initial | $424,983 | No comparison | 3 | SEC filing |
| Dec 28, 2020 | Initial | $1,457,000 | No comparison | 18 | SEC filing |
| May 1, 2020 | Initial | $1,915,000 | No comparison | 9 | SEC filing |
| Oct 9, 2019 | Initial | $5,951,093 | No comparison | 14 | SEC filing |
| Jul 20, 2018 | Initial | $2,000,000 | No comparison | 6 | SEC filing |
| Dec 19, 2017 | Initial | $200,000 | No comparison | 1 | SEC filing |
| Apr 26, 2016 | Initial | $385,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-529724
U.S. dollars have been converted from Canadian dollars based on the 0.7228 Bank of Canada daily exchange rate on 10-21-24. Total Remaining to be Sold represents the aggregate exercise price of issued options.
Source: Form D, filed Nov 18, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Rob Bakshi | Director |
| Rajeev Bakshi | Director |
| Kenneth Cawkell | Director, Executive |
| Lauren D'angelo | Executive |
| Henry Du | Executive |
| Anthony Giovinazzo | Director |
| John Havens | Director |
| Don Kalkofen | Executive |
| Denis Kay | Executive |
| Alfred Maelicke | Director |
| Michael Mc Fadden | Director, Executive |
| Len Mertz | Director |
| Jeremy Mertz | Director |
| Phillip Mertz | Director |
| Erich Mohr | Director |
| Frederick Sancilio | Director |
| Jeremy Wright | Executive |
| Jay Yoo | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1200 750 West Pender Street
Vancouver, A1, V6C 2T8
Vancouver, A1, V6C 2T8